Clinical Trial Update: Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections [Phase 2]

View source ↗

Summary

Phase 2 trial update on safety and efficacy of multiple daily dosing of oral LFF571 in patients with moderate Clostridium difficile infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• LFF571 (LFF571)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Moderate Clostridium Difficile Infection | Phase 2 | Status: COMPLETED